Recommendations

Most Recent

Sproutly Canada Inc.

Capital Cube (7/1/19) "SPR has enough money to finance its operations for a year."

DURECT Corp.

Francois Brisebois, Laidlaw & Company (6/27/19) "DRRX's capital raise takes care of financing overhang on the stock."

DURECT Corp.

Brian Marckx, Zacks Small-Cap Research (6/27/19) "The market for DRRX's POSIMIR could be substantial."

DURECT Corp.

Ed Arce, H.C. Wainwright & Co. (6/19/19) "DRRX can initiate the Phase 2a DUR-928 study's 150 mg dosing cohort."

Sproutly Canada Inc.

Jimmy Mengel, The Crow's Nest (5/31/19) "SPR struck a deal to develop its beverages with Moosehead Breweries."

Biotechnology / Pharmaceuticals

DURECT Corp.

Francois Brisebois, Laidlaw & Company (6/27/19) "DRRX's capital raise takes care of financing overhang on the stock."

DURECT Corp.

Brian Marckx, Zacks Small-Cap Research (6/27/19) "The market for DRRX's POSIMIR could be substantial."

DURECT Corp.

Ed Arce, H.C. Wainwright & Co. (6/19/19) "DRRX can initiate the Phase 2a DUR-928 study's 150 mg dosing cohort."

DURECT Corp.

Brian Marckx, Zacks Small-Cap Research (5/16/19) "Early data from DRRX's Phase 2a trial in AH are highly compelling."

ProMIS Neurosciences Inc.

Cosme Ordonez, Noble Capital Markets (5/15/19) "PMN presented progress in its Parkinson's program, at AP/PD 2019."

Nutraceuticals

Avivagen Inc.

Clive Maund, CliveMaund.com (5/11/19) "This looks like an excellent point to buy back VIV."